Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 19/20 | 0.64 |
| ▸ | MMP2 | P08253 | 4/20 | 0.64 |
| ▸ | MMP3 | P08254 | 3/20 | 0.64 |
| ▸ | MMP9 | P14780 | 3/20 | 0.64 |
| ▸ | MMP13 | P45452 | 3/20 | 0.64 |
| ▸ | MMP17 | Q9ULZ9 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880152 | 1.00 | ADAM17 (0.64) | ADAM17MMP2MMP3MMP9MMP13 | |
| SCHEMBL3879762 | 0.83 | ADAM17 (0.56) | ADAM17MMP2MMP3MMP9MMP13 | |
| SCHEMBL3879766 | 0.83 | ADAM17 (0.56) | ADAM17MMP2MMP3MMP9MMP13 | |
| SCHEMBL3881576 | 0.81 | ADAM17 (0.77) | ADAM17MMP2MMP3MMP9MMP13 | |
| SCHEMBL3880976 | 0.79 | ADAM17 (0.74) | ADAM17MMP2MMP3MMP9MMP13 | |
| SCHEMBL3880533 | 0.78 | ADAM17 (0.59) | ADAM17MMP2MMP3MMP9MMP13 | |
| SCHEMBL3883766 | 0.76 | ADAM17 (1.00) | ADAM17MMP2MMP3MMP9MMP13 | |
| SCHEMBL3881123 | 0.75 | ADAM17 (0.64) | ADAM17MMP2MMP3MMP9MMP13 | |
| SCHEMBL3881118 | 0.75 | ADAM17 (0.64) | ADAM17MMP2MMP3MMP9MMP13 | |
| SCHEMBL3881475 | 0.74 | ADAM17 (0.61) | ADAM17MMP2MMP3MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511144-B2 | Reverse hydroxamic acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| EP-1431285-B1 | REVERSE HYDROXAMIC ACID DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | STUDOR S.A. (LU) | 2004-12-02 | — | — | US | disclosed |
| EP-1431285-A1 | REVERSE HYDROXAMIC ACID DERIVATIVES | Kaken Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | TNF, RNASE1, IFNAR1 | ADAM17 20/4885MMP2 58/4885MMP3 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.